Compare Eaton Corporation plc (ETN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Novo Nordisk A/S — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Eaton Corporation plc and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Novo Nordisk A/S for 116 Days on average.
| ETN | NVO | |
|---|---|---|
Market Cap | $164.88B | $165.31B |
Volume | 2,535,086 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $459.96 | $63.98 |
52-Week Low | $315.82 | $35.29 |
Typical Hold Time | 31 Days | 116 Days |
Enterprise Value | $185.51B | $179.56B |
Dividend Yield | 1.04% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $424.51, down 1.58% on the day, amid a near-term bearish technical signal. The company demonstrates strong fundamental health with consistent earnings beats in recent quarters, a 12.75% net income margin, and robust revenue growth, reaching $30.0B in 2026. Recent strategic acquisitions, such as the COL Group announced on September 25, 2026, aim to expand its footprint in high-growth data center and utility markets.
The outlook is supported by a unanimous bullish analyst consensus with a $502.38 price target, though risks include a high P/E ratio of 43.23 and significant capital expenditure reflected in the 2026 investing cash flow of -$12.3B. The stock's near-term performance hinges on the upcoming Q3 2026 earnings result against a $3.53 EPS expectation.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
